Does starting MS drug earlier lead to better results?

This study observes people with relapsing multiple sclerosis in Austria to see if starting the drug Ofatumumab (Kesimpta) early in their disease journey leads to better outcomes than starting it later. It follows 106 patients for two years, comparing those who start the drug soon after diagnosis or within three years of their first treatment to those who switch to it after at least three years on other medications. The main goal is to see which group has better disease control, measured by factors like fewer relapses and less disability progression.